David Bouchey
Stock Analyst at Aegis Capital
(n/a)
# 4,441
Out of 4,834 analysts
6
Total ratings
n/a
Success rate
-61.09%
Average return
Main Sectors:
Stocks Rated by David Bouchey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SBFM Sunshine Biopharma | Reiterates: Buy | $15 | $1.41 | +963.83% | 2 | Dec 5, 2024 | |
| STSS Sharps Technology | Initiates: Buy | $105,600 | $4.55 | +2,320,779.12% | 1 | May 9, 2023 | |
| IINN Inspira Technologies Oxy B.H.N. | Maintains: Buy | $10 → $13 | $0.53 | +2,352.83% | 1 | Jan 25, 2023 | |
| RMTI Rockwell Medical | Downgrades: Outperform | $121 | $1.01 | +11,880.20% | 2 | Oct 19, 2018 |
Sunshine Biopharma
Dec 5, 2024
Reiterates: Buy
Price Target: $15
Current: $1.41
Upside: +963.83%
Sharps Technology
May 9, 2023
Initiates: Buy
Price Target: $105,600
Current: $4.55
Upside: +2,320,779.12%
Inspira Technologies Oxy B.H.N.
Jan 25, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $0.53
Upside: +2,352.83%
Rockwell Medical
Oct 19, 2018
Downgrades: Outperform
Price Target: $121
Current: $1.01
Upside: +11,880.20%